All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-05-19T07:08:05.000Z

The epidemiology and risk of mortality for patients with psoriatic arthritis

May 19, 2022
Share:
Learning objective: After reading this article, learners will be able to describe the global prevalence and incidence of psoriatic arthritis (PsA) and its impact on mortality.

Bookmark this article

Prevalence and incidence of PsA in general population1

In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. In Japan and Norway, the estimated prevalence of PsA has been recorded as 1 and 670 cases per 100,000, respectively. A high degree of variation in PsA incidence has also been found both between and within continents (Figure 1).

Figure 1. Incidence of PsA in the general population*

CASPAR, Classification of Psoriatic Arthritis; CI, confidence interval; ESSG, European Spondylarthropathy Study Group; ICD, International Classification of Diseases; M/F, male to female; M&W, Moll and Wright criteria; NR, not reported; PsA, psoriatic arthritis; RF, rheumatoid factor.
*Adapted from Karmacharya, et al.1

The ClASsification of Psoriatic ARthritis (CASPAR) criteria was developed in 2006, which provided some uniformity in defining PsA, though not all studies use this system as it requires a physical examination of the patient. Studies that used the International Classification of Diseases (ICD) codes found the lowest prevalence of PsA, whereas studies that used self-reported PsA diagnoses reported the highest prevalence.

Most studies of prevalence trends of PsA have shown an increase in recent years. No clear sex predominance has been identified, with studies from different countries finding opposing results. For example, a higher prevalence in males was recorded in Norway and Argentina, whereas in the Czech Republic and Denmark, a greater prevalence of PsA was noted in females.

PsA prevalence and incidence in patients with psoriasis

In patients with psoriasis there is also variability in the prevalence of PsA recorded by different studies. One study reported a prevalence of PsA in patients with psoriasis of 19.7% (95% confidence interval, 18.5−20.9%), with adults having a much higher prevalence than children/teenagers at 21.6% vs 3.3%, respectively. In addition, a higher prevalence of PsA was noted in patients with moderate to severe (24.6%) compared with mild (15.8%) psoriasis.

The prevalence of PsA in patients with psoriasis has been shown to be variable between continents:

  • Asia, 14.0%
  • Africa, 15.5%
  • North America, 19.5%
  • South America, 21.5%
  • Europe, 22.7%

The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4% (Figure 2).

Figure 2. Incidence of PsA among patients with psoriasis*

CASPAR, Classification of Psoriatic Arthritis; CI, confidence interval; M/F, male to female; NR, not reported; PsA, psoriatic arthritis.
*Adapted from Karmacharya, et al.1

Mortality

Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5 (Figure 3). Older studies may show a higher SMR than more recent ones.

Figure 3. Mortality of PsA: overall and cause-specific*

aHR, adjusted hazard ratio; CASPAR, Classification of Psoriatic Arthritis; CHF, congestive heart failure; CI, confidence interval; CVA, cerebrovascular accident; ESSG, European Spondylarthropathy Study Group; HR, hazard ratio; ICD, International Classification of Diseases; MI, myocardial infarction; NR, not recorded; PsA, psoriatic arthritis; RR, relative risk; SHR, standardized hazard ratio; SMR, standardized mortality rate; TB, tuberculosis.
*Adapted from Karmacharya, et al.1

A prospective study from the University of Toronto has demonstrated decreased mortality risk over time across almost four decades of follow-up:

  • from 1978 to 1986, the SMR was 1.89;
  • from 1987 to 1995, the SMR was 1.83;
  • and from 1996 to 2004, the SMR was 1.21.

A more recent study from 1978 to 2017 showed no increase in overall mortality rate, with an SMR of 0.92 (95% confidence interval, 0.81−1.05). While evidence is currently contradictory regarding the impact of PsA on cardiovascular mortality, some studies have shown an increase in risk. Occasionally, cause-specific mortality for respiratory diseases has also been linked to PsA; however, again the data are conflicting.

Conclusion

While an increasing trend in PsA prevalence has been seen in recent years, PsA remains underdiagnosed. The development of PsA is complex and multifactorial. Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

  1. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. DOI: 1016/j.berh.2021.101692

More about...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox